Department of General Dentistry, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, PR China.
Mol Genet Genomic Med. 2019 Aug;7(8):e857. doi: 10.1002/mgg3.857. Epub 2019 Jul 15.
Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide, exhibiting high morbidity and mortality. The prognosis of HNSCC patients has remained poor, though considerable efforts have been made to improve the treatment of this cancer. Therefore, identifying significant differentially expressed genes (DEGs) involved in HNSCC progression and exploiting them as novel biomarkers or potential therapeutic targets for HNSCC is highly valuable.
Overlapping differentially expressed genes (DEGs) were screened out from three independent gene expression omnibus (GEO) datasets and subjected to GO and kyoto encyclopedia of genes and genomes pathway enrichment analyses. The protein-protein interactions network of DEGs was constructed in the STRING database, and the top ten hub genes were selected using cytoHubba. The relative expression of hub genes was detected in GEPIA, Oncomine, and human protein atlas (HPA) databases. Furthermore, the relationship of hub genes with the overall survival and disease-free survival in HNSCC patients was investigated using the cancer genome atlas data.
The top ten hub genes (SPP1, POSTN, COL1A2, FN1, IGFBP3, APP, MMP3, MMP13, CXCL8, and CXCL12) could be utilized as potential diagnostic indicators for HNSCC. The relative levels of FN1, APP, SPP1, and POSTN could be associated with the prognosis of HNSCC patients. The mRNA expression of APP and COL1A2 was validated in HNSCC samples.
This study identified effective and reliable molecular biomarkers for diagnosis and prognosis by integrated bioinformatics analysis, suggesting novel and essential therapeutic targets for HNSCC.
头颈部鳞状细胞癌（HNSCC）是全球最常见的癌症之一，具有较高的发病率和死亡率。尽管为改善这种癌症的治疗做出了相当大的努力，但 HNSCC 患者的预后仍然很差。因此，鉴定与 HNSCC 进展相关的重要差异表达基因（DEGs），并将其用作 HNSCC 的新型生物标志物或潜在治疗靶点是非常有价值的。
从三个独立的基因表达综合（GEO）数据集筛选出重叠的差异表达基因（DEGs），并进行 GO 和京都基因与基因组百科全书通路富集分析。在 STRING 数据库中构建 DEGs 的蛋白质-蛋白质相互作用网络，使用 cytoHubba 选择前 10 个枢纽基因。在 GEPIA、Oncomine 和人类蛋白质图谱（HPA）数据库中检测枢纽基因的相对表达。此外，使用癌症基因组图谱数据研究了枢纽基因与 HNSCC 患者总生存期和无病生存期的关系。
前 10 个枢纽基因（SPP1、POSTN、COL1A2、FN1、IGFBP3、APP、MMP3、MMP13、CXCL8 和 CXCL12）可作为 HNSCC 的潜在诊断指标。FN1、APP、SPP1 和 POSTN 的相对水平可能与 HNSCC 患者的预后相关。在 HNSCC 样本中验证了 APP 和 COL1A2 的 mRNA 表达。
本研究通过整合生物信息学分析，鉴定出用于诊断和预后的有效和可靠的分子生物标志物，为 HNSCC 提供了新的、重要的治疗靶点。
Zotero 插件
